DRTSW
OtherAlpha Tau Medical Ltd - Warrants (07/03/2027)
$0.95-0.04 (-4.04%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving DRTSW Today?
No stock-specific AI insight has been generated for DRTSW yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.20$1.50
$0.95
Fundamentals
Market Cap—
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin—
Debt / Equity—
Trading
Volume1K
Avg Volume (10D)—
Shares Outstanding—
DRTSW News
19 articles- Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent GlioblastomaYahoo Finance·May 8, 2026
- Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell CarcinomaYahoo Finance·May 8, 2026
- Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT® Head and Neck Cancer Combination with PembrolizumabYahoo Finance·May 5, 2026
- Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026Yahoo Finance·May 4, 2026
- Alpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT Pancreatic Cancer StudiesYahoo Finance·Apr 27, 2026
- Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel)Yahoo Finance·Apr 23, 2026
- Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Europe with Alpha DaRT® in French Multicenter ACAPELLA Clinical TrialYahoo Finance·Apr 23, 2026
- Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026Yahoo Finance·Mar 31, 2026
- Alpha Tau Medical Conference: Japan Approval, Rolling FDA PMA, and Big 2026 Data Readouts TeasedMarketbeat·Mar 19, 2026
- HekaBio and Alpha Tau Medical Obtain Approval in Japan for Solid Tumor Treatment Alpha DaRTYahoo Finance·Feb 25, 2026
- Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck CancerYahoo Finance·Feb 24, 2026
- Alpha Tau to Participate at Jefferies Global Healthcare Conference in LondonYahoo Finance·Nov 11, 2025
- Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial ReadinessYahoo Finance·Oct 21, 2025
- Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical TrialYahoo Finance·Sep 2, 2025
- Alpha Tau to Participate in Five September Investor ConferencesYahoo Finance·Aug 27, 2025
- Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Aug 11, 2025
- Alpha Tau to Present at Jefferies Global Healthcare ConferenceYahoo Finance·May 28, 2025
- Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate UpdateYahoo Finance·May 19, 2025
- Alpha Tau Announces Appointment of Nadav Kidron to its Board of DirectorsYahoo Finance·May 12, 2025
All 19 articles loaded
Price Data
Open$1.00
Previous Close$0.99
Day High$1.00
Day Low$0.91
52 Week High$1.50
52 Week Low$0.20
52-Week Range
$0.20$1.50
$0.95
Fundamentals
Market Cap—
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin—
Debt / Equity—
Trading
Volume1K
Avg Volume (10D)—
Shares Outstanding—
About Alpha Tau Medical Ltd - Warrants (07/03/2027)
Alpha Tau Medical Ltd., a clinical-stage oncology therapies company, is engaged in the research, development, and commercialization of alpha-emitting radiation therapy (Alpha DaRT) for the treatment of solid cancer in Israel and the United States. The company is headquartered in Jerusalem, Israel.
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SIC—
CIK—
Composite FIGI—
Share Class FIGI—